Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Review Article

Cancer Stem Cells and Anti-tumor Immunity

Author(s): Merve Yılmaz, Fuat Kaplan, Ilgen Mender, Sergei M. Gryaznov and Z. Gunnur Dikmen*

Volume 18, Issue 4, 2023

Published on: 11 November, 2022

Page: [445 - 459] Pages: 15

DOI: 10.2174/1574888X18666221017142032

Price: $65

Abstract

Cancer stem cells (CSCs) are correlated with poor clinical outcomes due to their contribution to chemotherapy resistance and the formation of metastasis. Multiple cell surface and enzymatic markers have been characterized to identify CSCs, which is important for diagnosis, therapy, and prognosis. This review underlines the role of CSCs and circulating tumor cells (CTCs) in tumor relapse and metastasis, the characteristics of CSC and CTC biomarkers, and the techniques used to detect these cells.

We also summarized novel therapeutic approaches toward targeting CSCs, especially focusing on the role of immune checkpoint blockades (ICB), such as anti-programmed death 1 (anti-PD1) and antiprogrammed death ligand-1 (anti-PDL1) therapies. Additionally, we address an intriguing new mechanism of action for small molecular drugs, such as telomere-targeted therapy 6-thio-2’deoxyguanosine (6- thio-dG), and how it reshapes tumor microenvironment to overcome ICB resistance. There are indications, that personalized cancer therapy targeting CSC populations in conjunction with immune-mediated strategy hold promise for the removal of residual therapy-resistant CSCs in the near future.

Keywords: Cancer stem cells, surface markers, functional assays, Circulating tumor cells, anti-tumor immunity, immune checkpoint blockades (ICB).


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy